News | November 08, 2023
Evonik launches GMP-quality plant-based squalene
PhytoSquene now available for clinical and commercial use
PhytoSquene now available for clinical and commercial use
This product will be manufactured at Lupin’s Pithampur facility in India
This product will be manufactured at Lupin's Nagpur facility in India
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
NATCO's Pharmacovigilance Department was inspected from October 30, 2023 to November 1, 2023
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
India is following a holistic and inclusive approach in alignment with the vison of Universal Health Coverage and the resolute commitment to ‘leave no one behind
The companies plan to start a pivotal Phase 3 trial in the coming months
RHTC will address a long-standing healthcare access issue for all the local population
Approval based on DESTINY-Lung02 results where AstraZeneca and Daiichi Sankyo’s Enhertu demonstrated a confirmed objective response rate of 49% and median duration of response of 16.8 months in previously treated patients
Subscribe To Our Newsletter & Stay Updated
